NYSE
$1.64▲ 1.23%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $187.0MShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
31- 1d agoRegular26.10.23 23:528-KKey event#●●●#●●●#●●●
Perspective Therapeutics, Inc.Bullish
Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors, showing objective response rates of 33% in Cohort 2 and 50% in Cohort 3. The treatment was well-tolerated with no dose-limiting toxicities reported. The company aims to complete Phase 3 preparations by the end of 2026 and initiate the study in 2027.…more
$1.64+1.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.8Pre-market26.10.08 19:288-KKey event
Perspective Therapeutics, Inc.
Perspective Therapeutics has been granted Fast Track Designation by the U.S. FDA for the development of PSV359 for adult patients with FAP-positive solitary fibrous tumors. This designation allows the company to benefit from more frequent interactions with the FDA to expedite the development and review process.…more
$1.64+1.23%vs prev closeView filingShare - 10.1After-hours26.10.02 05:088-KKey event
Perspective Therapeutics, Inc.
Perspective Therapeutics released an updated corporate presentation on October 1, 2026, detailing the clinical progress of its radiopharmaceutical pipeline. The company highlighted its strategy for developing targeted oncology therapies through three independent clinical-stage programs, including VMT-α-NET, VMT01, and PSV359.…more
$1.64+1.23%vs prev closeView filingShare
30 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.23 23:54#●●●#●●●
Perspective Therapeutics Presents Interim Phase 1/2a Data for Neuroendocrine Tumor Candidate…more
Perspective Therapeutics announced interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET for neuroendocrine tumors at the ESMO Congress 2026. The data highlights the candidate's performance in patients with unresectable or metastatic SSTR2-expressing tumors.…more
$1.64+1.23%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 1d agoRegular26.10.23 23:49
●●●●●●●● ●●●●● ●●●●●●
Perspective Therapeutics announced promising interim results from its Phase 1/2a trial, demonstrating robust tumor response and a favorable safety profile for its SSTR2-targeting radiopharmaceutical. The company plans to initiate Phase 3 clinical trials in 2027 following regulatory alignment.…more
$1.64+1.23%vs prev close - 10.8Pre-market26.10.08 19:16
●●●●●●●● ●●●●● ●●●●●●
Perspective Therapeutics announced that its investigational cancer therapy PSV359 has been granted FDA Fast Track designation to expedite development. While this facilitates regulatory interaction, the company's long-term value remains dependent on upcoming clinical trial results.…more
$1.64+1.23%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report